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Abstract
Background: Remodeling of Ca2+ signaling is an important step in cancer progression, and altered expression of
members of the Ca2+ signaling toolkit including the plasma membrane Ca2+ ATPases (PMCA proteins encoded by
ATP2B genes) is common in tumors.
Methods: In this study PMCAs were examined in breast cancer datasets and in a variety of breast cancer cell lines
representing different subtypes. We investigated how estrogen receptor alpha (ER-α) and histone deacetylase
(HDAC) inhibitors regulate the expression of these pumps.
Results: Three distinct datasets displayed significantly lower ATP2B4 mRNA expression in invasive breast cancer
tissue samples compared to normal breast tissue, whereas the expression of ATP2B1 and ATP2B2 was not altered.
Studying the protein expression profiles of Ca2+ pumps in a variety of breast cancer cell lines revealed low PMCA4b
expression in the ER-α positive cells, and its marked upregulation upon HDAC inhibitor treatments. PMCA4b
expression was also positively regulated by the ER-α pathway in MCF-7 cells that led to enhanced Ca2+ extrusion
capacity in response to 17β-estradiol (E2) treatment. E2-induced PMCA4b expression was further augmented by
HDAC inhibitors. Surprisingly, E2 did not affect the expression of PMCA4b in other ER-α positive cells ZR-75-1, T-47D
and BT-474. These findings were in good accordance with ChIP-seq data analysis that revealed an ER-α binding site
in the ATP2B4 gene in MCF-7 cells but not in other ER-α positive tumor cells. In the triple negative cells PMCA4b
expression was relatively high, and the effect of HDAC inhibitor treatment was less pronounced as compared to
that of the ER-α positive cells. Although, the expression of PMCA4b was relatively high in the triple negative cells, a
fraction of the protein was found in intracellular compartments that could interfere with the cellular function of the
protein.
Conclusions: Our results suggest that the expression of Ca2+ pumps is highly regulated in breast cancer cells in a
subtype specific manner. Our results suggest that hormonal imbalances, epigenetic modifications and impaired
protein trafficking could interfere with the expression and cellular function of PMCA4b in the course of breast
cancer progression.
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Background
Breast cancer is the second most common cancer type
worldwide, and is the major cause of cancer death among
women according to the GLOBOCAN 2012 project [1].
Breast cancer is a very complex and heterogeneous disease
that can be divided into several subtypes based on gene ex-
pression profiles and immunohistochemical markers. These
subgroups also differ in their clinical outcomes, therapy re-
sponses and metastatic potential. Approximately 75% of
breast cancers belong to the luminal A or B subtype, which
are more differentiated breast tumors and express estrogen
receptor alpha (ER-α) and/or progesterone receptor (PR).
These cancers respond well to anti-estrogen therapy; how-
ever, recurrence is frequent. About 20% of breast cancers,
that overexpress human epidermal growth factor receptor 2
(HER2) can be treated with targeted therapies against
HER2. The most aggressive, triple negative (ER-, PR-,
HER2-) basal and claudin-low subtypes still lack druggable
targets; the only option for the systemic treatment of these
tumors is chemotherapy [2, 3]. Therefore, breast cancer re-
search aims to find new targets and new biomarkers that
can predict therapy response or resistance. Recent studies
suggest that targeting the PI3K/Akt/mTOR and FGFR or
IGFR pathways, using PARP inhibitors, epigenetic modula-
tors such as histone deacetylase (HDAC) inhibitors, or im-
munotherapies are the most promising pharmacological
therapeutic opportunities [4–6]. HDAC inhibitors alone or
in combination with other treatment options are under clin-
ical investigation for the treatment of several solid malig-
nancies, including breast cancer. These compounds exert
their anticancer effects through inhibition of cell prolifera-
tion and induction of differentiation and cell death. Al-
though the results are promising, especially in case of the
combined therapies, the mechanisms of action are not com-
pletely understood [6–8].
The remodeling of cellular calcium (Ca2+) homeostasis
is an important step in cancer progression, because Ca2+
signaling is linked either directly or indirectly to the main
processes altered in tumorigenesis such as regulation of
proliferation, cell survival, migration or invasion [9, 10].
The expression of several Ca2+ channels or pumps show
characteristic changes during these processes, resulting in
altered Ca2+ signal patterns affecting further downstream
Ca2+-sensitive signaling pathways [9, 10]. Certain mem-
bers of the transient receptor potential (TRP) family of the
Ca2+ channels are frequently upregulated in various can-
cer types. Several studies have revealed the remodeling of
store-operated Ca2+ entry (SOCE) and showed altered
STIM and Orai protein expressions. Reduced expression
of various forms of Ca2+ pumps was also observed in a
variety of cancer types [9, 10]. The alteration of the sarco/
endoplasmic reticulum Ca2+ ATPase 3 (SERCA3) – a
SERCA-type Ca2+ pump – during tumorigenesis was con-
firmed in several different cancer types such as breast,
lung, brain, colon, gastric carcinomas or leukemias, using
either cancer cell lines or tissues [11–16].
Plasma membrane type Ca2+ pumps or Ca2+ ATPases
(PMCAs) are responsible for the expulsion of Ca2+ from
the cytosol into the extracellular space, to maintain a low
intracellular Ca2+ concentration [17]. In mammals, four
separate genes code for the major PMCA isoforms
(ATP2B1 ATP2B4 genes code PMCA1-PMCA4 proteins)
and alternative RNA splicing can generate additional
PMCA variants. The more than 20 splice variants show tis-
sue- and cell type-specific expression and differ in their cel-
lular localization and activity [18–20]. Since PMCA is a
major regulator of Ca2+ signaling in many non-excitable
cell types, it plays an essential role in the regulation of cell
proliferation, differentiation and apoptosis, processes closely
related to tumorigenesis [9, 20]. However, limited data are
available on PMCAs related to cancer. Studies on colon
cancer showed lower PMCA4 expression in tumors com-
pared to normal tissue [21, 22], while PMCA1 was found to
be downregulated in oral cancers [23]. Previous in vitro
studies showed upregulated ATP2B1 and ATP2B2 mRNA
and downregulated ATP2B4 mRNA expression in some
breast cancer cell lines [24, 25]. Moreover, high ATP2B2 ex-
pression in breast cancer was found to be associated with
specific tumor subtypes [26–28].
Previous studies have suggested that PMCAs can im-
pact on Ca2+ signaling in an isoform specific manner
[19]. Moreover, we found considerable PMCA4b upregu-
lation during HDAC inhibitor treatment of MCF-7
breast cancer cells, and this effect was further enhanced
by phorbol 12-myristate 13-acetate (PMA). The altered
PMCA4b expression led to enhanced Ca2+ clearance,
suggesting that the protein plays an important role in
the Ca2+ homeostasis of MCF-7 cells. Moreover, immu-
nohistochemical analysis of normal breast tissue showed
high PMCA4 expression in breast ductal epithelial cells,
suggesting that PMCA4 is an essential component of the
Ca2+ signaling toolkit in the normal breast epithelium
[29]. More recently, our group has found that HDAC in-
hibitors upregulated PMCA4b expression in melanoma
cell lines [30]. In addition, we showed that inhibition of
mutant B-Raf enhanced PMCA4b expression in BRAF
mutant melanoma cells, and that PMCA4b abundance
(induced either by overexpression or drug treatments)
was coupled with decreased migration and metastatic
activity of BRAF mutant melanoma cells [31]. These ob-
servations also highlight the importance of PMCA4b in
the development and progression of these tumor types.
In this study we investigated the expression of the
ATP2B genes in publicly available breast cancer gene ex-
pression datasets and studied the modulation of the ex-
pression of various Ca2+ pumps at the protein level by
HDAC inhibitor and/or 17β-estradiol (E2) treatments in a
variety of breast cancer cell lines. The examined cell line
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panel represents the non-tumorigenic breast epithelium,
the luminal A, luminal B and HER2 expressing, as well as
the triple negative, basal subtype breast tumors (see Add-
itional file 1: Table S1) [2, 3, 32–34]. Publicly available data
[35] revealed significantly lower ATP2B4 mRNA expression
in breast carcinomas when compared to normal breast tis-
sue. Protein levels of the PMCA and SERCA isoforms
showed high variability among the cell lines, and distinct
regulatory mechanisms of PMCA expression were observed
upon drug treatments or ER-α activation, depending on
tumor subtype.
Methods
Cell culture
The MCF-10A, MCF-7, ZR-75-1, BT-474, AU-565,
SK-BR-3 and Hs578T cell lines were obtained from the
American Type Culture Collection (ATCC). The T-47D,
MDA-MB-468, BT-549 and MDA-MB-231 cell lines were
obtained from NCI Development Therapeutics Program
(DCTD Tumor Repository, National Cancer Institute at
Frederick, MD). Stocks of frozen viable cells were generated
immediately after one or two passages, and low passage
number cells were used for all experiments. All cell lines
were tested for mycoplasma infection with MycoSensor
PCR Assay kit (Agilent Technologies) and only myco-
plasma free cells were used for the experiments. The
MCF-7, GCaMP2-MCF-7, SK-BR-3 and Hs578T cells were
cultured in DMEM supplemented with 10% FBS (Gibco,
Thermo Scientific), 100 U/ml penicillin, 100 μg/ml strepto-
mycin and 2 mM glutamine. The T-47D, ZR-75-1, BT-474,
AU-565, MDA-MB-468, BT-549, MDA-MB-231 and
GCaMP2-MDA-MB-231 cells were cultured in RPMI 1640
supplemented with 10% FBS (Gibco, Thermo Scientific),
100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM
glutamine. The MCF-10A cell line was cultured in MEGM
according to the instructions of ATCC. Cells were incu-
bated at 37 °C and 5% CO2 in a humidified atmosphere.
Stable GCaMP2 expressing cell lines
The GCaMP2-MCF-7 cell line was established previ-
ously as described in [29]. For further studies a similar
GCaMP2-MDA-MB-231 cell line was generated using
the Sleeping Beauty transposon system, as described
earlier [29].
Reagents and treatments
Valproic acid sodium salt (VPA; Sigma-Aldrich) was dis-
solved in sterile distilled water, membrane filtered and
stored at − 20 °C. Suberoylanilide hydroxamic acid (SAHA;
Sigma-Aldrich), 17β-estradiol (E2; Sigma-Aldrich) and ful-
vestrant (ICI 182,780; Sigma-Aldrich) stock solutions were
made in DMSO and stored at − 20 °C. The final DMSO
concentration did not exceed 0.01% in all experiments,
DMSO vehicle was included in controls and did not inter-
fere with the experiments.
For HDAC inhibitor treatments, exponentially growing
cells were seeded in 6-well plates for Western blotting or in
8-well chambers (Nunc Lab-Tek II chambered coverglass,
Thermo Scientific) for immunocytochemistry and Ca2+ sig-
nal measurements, and incubated for 3 days until cultures
reached ~ 80% confluency. Culture medium was then re-
placed by fresh medium, and VPA or SAHA was added
from concentrated stock solutions. During SAHA treat-
ment the medium was replaced daily. After 4 days of treat-
ment, protein expressions were analyzed by Western
blotting or by immunocytochemistry, or Ca2+ signal mea-
surements were performed. In the case of E2 treatments,
cells were incubated in E2-free culture medium (DMEM
w/o phenol red or RPMI 1640 w/o phenol red, supple-
mented with 10% charcoal-stripped FBS (Gibco, Thermo
Scientific), 100 U/ml penicillin, 100 μg/ml streptomycin
and 2 mM glutamine). For Western blotting or Ca2+ signal
measurements cells were seeded in 6-well plates or in
8-well chambers (Nunc Lab-Tek II chambered coverglass,
Thermo Scientific) respectively, in normal growth medium,
and after 1 day medium was replaced by E2-free medium,
and cells were incubated for 2 days until cultures reached
~ 80% confluency. E2-free medium was then renewed, and
cells were treated with 1 nM E2 with or without 100 nM
fulvestrant and the indicated amount of HDAC inhibitors.
After 4 days of treatment, protein expressions were ana-
lyzed or Ca2+ signal measurements were performed.
Western blot analysis
Total protein extraction from the cells was obtained by pre-
cipitation with 6% TCA, and Western blotting was per-
formed as described previously [36]. Equal amounts of total
cellular protein were loaded on polyacrylamide gels (7.5, 10
or 15% depending on the examined protein), electropho-
resed and electroblotted onto PVDF membranes (Bio-Rad).
Immunostainings were performed with the following pri-
mary antibodies: mouse monoclonal anti-pan PMCA
(5F10), rabbit polyclonal anti-PMCA1 (NR1), rabbit poly-
clonal anti-PMCA2 (NR2), rabbit polyclonal anti-PMCA3
(NR3), mouse monoclonal anti-PMCA4 (JA9), and
mouse monoclonal anti-PMCA4b (JA3) described in
[37, 38], mouse monoclonal anti-SERCA2 antibody
(IID8; Sigma-Aldrich), mouse monoclonal anti-SERCA3
(PL/IM430; [39]), mouse monoclonal anti-β-actin (AC-15;
Sigma-Aldrich), mouse monoclonal anti-ER-α (6F11; Invi-
trogen), rabbit polyclonal anti-ER-β (Invitrogen) and rabbit
polyclonal anti-acetyl-histone H3 (Lys9/Lys14) (Cell Signal-
ing). Signals of the secondary, HRP-conjugated anti-mouse
or anti-rabbit antibodies (Jackson ImmunoResearch) were
detected using the Pierce ECL Western Blotting Substrate
(Thermo Scientific) and luminography on CL-XPosure Film
(Thermo Scientific) or Amersham Hyperfilm ECL (GE
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Healthcare) films. Densitometric analyses were carried out
using the ImageJ software v1.51j8, and data were processed
with the Prism 4 software v4.01 (GraphPad Software) and
expressed as means ± SEM.
Immunocytochemistry
The procedure of immunocytochemical staining was per-
formed as described previously [29] with a mouse mono-
clonal anti-PMCA4b (JA3) primary antibody [37] and an
Alexa Fluor 488-conjugated anti-mouse IgG secondary
antibody (Invitrogen). Images were taken by a Zeiss
LSM710 confocal laser scanning microscope equipped
with a Plan-Apochromat 63×/1.40 oil immersion objective
and Zeiss ZEN software. Images of control and treated
wells from the same cell line were taken with the same
microscope settings.
Ca2+ signal measurement
GCaMP2-MCF-7 and GCaMP2-MDA-MB-231 cell lines
were used for Ca2+ signal measurements after VPA treat-
ment. Cells were treated with 4 mM VPA for 4 days. In the
case of E2 treatments, GCaMP2-MCF-7 cells were preincu-
bated in E2-free DMEM (DMEM w/o phenol red, supple-
mented with 10% charcoal-stripped FBS (Gibco), 100 U/ml
penicillin, 100 μg/ml streptomycin and 2 mM glutamine)
for 2 days and then treated with 1 nM E2 for 4 days. Imme-
diately before the Ca2+ signal measurement, medium was
replaced by HBSS supplemented with with 0.9 mM MgCl2,
2 mM CaCl2 and 20 mM HEPES; pH 7.4. Ca
2 influx was
triggered by the addition of 2 μM A23187 (Sigma-Aldrich).
Fluorescent signal of the GCaMP2 Ca2+ sensor was de-
tected by confocal imaging with a Zeiss LSM710 confocal
laser scanning microscope and Plan-Apochromat 63×/1.40
oil immersion objective. Time lapse images were recorded
every 0.3 s at room temperature with the Zeiss ZEN soft-
ware. Data were analyzed with the ImageJ software v1.51j8
and Prism 4 software v4.01 (GraphPad Software). The rela-
tive fluorescence intensities were calculated as F/F0 (where
F0 was the average initial fluorescence) and are expressed
as means ±95% CI. Statistical significance was calculated
by t-test, *** means P < 0.001, ** means P < 0.01, * means
P < 0.05, n.s. means not significant.
Analysis of publicly available ChIP-seq data
ChIP-seq data analysis was performed using the Cistrome
Data Browser [40, 41]. Used raw data from the Gene Ex-
pression Omnibus (GEO) [42, 43] are: GSM798428 (ER-α
Chip-seq data in T-47D cells, this data sample is in the GEO
data series GSE32222 [44]), GSM798424 (ER-α Chip-seq
data in MCF-7 cells, this data sample is in the GEO data
series GSE32222 [44]), GSM986089 (ER-α Chip-seq data in
ZR-75-1 cells, this data sample is in the GEO data series
GSE40129 [45]), GSM986063 (ER-α Chip-seq data in
MCF-7 cells, this data sample is in the GEO data series
GSE40129 [45]), GSM2040043 (ER-α Chip-seq data in
MCF-7 cells [46]), GSM2467223 (ER-α Chip-seq data in
MCF-7 cells [Dzida et al., unpublished]). Chip-seq data were
visualized using the UCSC Genome Browser [47, 48] on
Human Dec. 2013 (GRCh38/hg38) Assembly.
Results
ATP2B4 gene expression is downregulated in breast
carcinomas
In our previous study immunohistochemical staining of
breast tissue indicated the presence of PMCA4 (ATP2B4)
protein in normal breast ductal epithelium [29]. Here, we
evaluated the expression of the ATP2B family members in
breast cancer tissues analyzing data from three individual
gene expression datasets using the Oncomine database
[35]. We found that the expression of the ATP2B4 gene
was downregulated in invasive breast carcinoma or invasive
ductal breast carcinoma samples compared to normal
breast tissues (Fig. 1). In contrast, the expression of the
ATP2B1 and ATP2B2 genes was not altered in breast can-
cer tissues. Next we studied Ca2+ pump expressions in vitro
in a set of breast cancer cell lines representing all breast
tumor types, at the protein level.
Different breast cancer subtypes have different Ca2+
pump expression patterns
We examined the expression of PMCA and SERCA pro-
teins in a variety of breast carcinoma cell lines (see Add-
itional file 1: Table S1) by Western blotting, using isoform
specific antibodies (Fig. 2). Low PMCA4b expression was
found in the luminal subtype and HER2 overexpressing
cells, whereas the triple negative, basal cancer cells, repre-
senting a more aggressive breast cancer subtype showed
high PMCA4b and PMCA1 expression levels. PMCA2 spe-
cific staining was very low in all cell types, and no PMCA3
was found in any of the examined cell lines. SERCA3 was
expressed in all luminal subtypes and HER2 overexpressing
cells, while it was totally absent in the triple negative cells,
including also the non-tumorigenic MCF-10A line. This
correlates well with previous observations showing that
triple negative ductal breast carcinomas have reduced
SERCA3 expression [15]. The housekeeping SERCA2 pro-
tein was present in all cell types at a relatively high
abundance.
Expression of Ca2+ pumps is modulated by HDAC
inhibition in a cell type specific manner
Previously we reported that HDAC inhibitor and PMA
treatments caused pronounced elevation in the mRNA and
protein expression levels of PMCA4b in MCF-7 cells [29].
Here we treated different breast cancer cell lines and the
non-tumorigenic MCF-10A cells with the FDA-approved
HDAC inhibitor valproate (VPA) or suberoylanilide hydro-
xamic acid (SAHA; Vorinostat), which are currently tested
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in clinical trials for breast cancer treatment [6–8]. We
found a substantial upregulation of PMCA4b expression in
the luminal subtype cell lines (MCF-7, ZR-75-1, BT-474)
and in the HER2 overexpressing SK-BR-3 cell line. The up-
regulation was less pronounced in all triple negative, basal
type cancer cells, MDA-MB-468, BT-549, MDA-MB-231,
Hs578T and in the non-tumorigenic MCF-10A cell line
and in the HER2 positive AU-565 cells. It is important to
emphasize that the basal type cells that included the
non-tumorigenic MCF-10A cells, as well, had already high
PMCA4b levels without any treatments (Fig. 3a-b).
PMCA4b expression decreased after treatments with high
Fig. 1 ATP2B4 gene expression is downregulated in breast carcinomas compared to normal breast tissue. ATP2B1, ATP2B2 and ATP2B4 gene
expression data were obtained from the Oncomine database [35]. a: Relative gene expression of normal (n = 4) vs. invasive breast carcinoma
(n = 154) tissues from the „Gluck breast” study [76]. ATP2B1: fold change: 1.069; P-value: 0.358; t-test: 0.396. ATP2B2: fold change: 1.919; P-value:
0.155; t-test: 1.215. ATP2B4: fold change: − 2.606; P-value: 0.013; t-test: − 3.974. b: Relative gene expression of normal (n = 61) vs. invasive ductal
breast carcinoma (n = 389) tissues from „TCGA breast” study (2011). ATP2B1: fold change: − 1.093; P-value: 0.096; t-test: -1.314. ATP2B2: fold change:
1.095; P-value: 0.067; t-test: 1.513. ATP2B4: fold change: − 2.161; P-value: 7.79 e-15; t-test: − 9.455 c: Relative gene expression of normal (n = 144) vs.
invasive ductal breast carcinoma (n = 1556) tissues from „Curtis breast” study [77]. ATP2B1: fold change: − 1.013; P-value: 0.158; t-test: -1.006.
ATP2B2: fold change: 1.029; P-value: 0.001; t-test: 3.040. ATP2B4: fold change: − 2.061; P-value: 5.33 e-40; t-test: − 17.593
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concentration VPA or SAHA in case of AU-565 and
SK-BR-3 cells, suggesting that these cell lines are more sen-
sitive to prolonged treatments with high dosage HDAC in-
hibitors that may induce cell death. Elevation of the
PMCA1 isoform was induced only in ZR-75-1 and BT-549
cells, and SERCA2 and SERCA3 expressions changed only
slightly upon HDAC inhibitor treatments (see Add-
itional file 2: Figure S1).
Previous studies have shown that HDACs are overex-
pressed in ER-α positive breast tumors, and HDAC1,
HDAC3 and HDAC6 protein expressions correlate with
ER-α expression [49, 50]. Therefore, we examined the level
of histone H3 acetylation after HDAC inhibitor treatments
in the investigated cell lines. We found considerable upreg-
ulation of histone H3 acetylation in the ER-α positive
breast cancer cells in response to HDAC inhibition that
correlated well with PMCA4b expression (see Add-
itional file 3: Figure S2). These results suggest that alter-
ation in histone acetylation levels is involved in the
regulation of PMCA4b expression. However, we could not
detect such a close correlation between PMCA4b expres-
sion and histone H3 acetylation in the case of the HER2
positive and triple negative cell lines. PMCA4b was found
to be upregulated in the HER2 positive SK-BR-3 cell line
without considerable enhancement of histone H3 acetyl-
ation, whereas in the triple negative BT-549 cells, HDAC
Fig. 2 Diverse Ca2+ pump expressions were found in breast tumor cell lines representing different subtypes. Basal protein expression of PMCA
and SERCA isoforms was analyzed by Western blotting in different breast cancer cell lines. a: Equal amount (30 μg) of total cell protein lysates of
confluent cell cultures were immunostained with isoform specific antibodies: anti-pan-PMCA (5F10), anti-PMCA1 (NR1), anti-PMCA2 (NR2), anti-
PMCA3 (NR3), anti-PMCA4 (JA9), anti-PMCA4b (JA3), anti-SERCA2 (IID8) and anti-SERCA3 (PL/IM 430). β-actin served as a loading control.
Microsomal membrane preparations isolated from COS-7 cells were used as isoform-specific positive controls: PMCA1: 1 μg membrane protein
from untransfected cells; PMCA2: a mixed sample of 0.1–0.1 μg membrane protein from cells transfected with rPMCA2a, rPMCA2b, hPMCA2wb
constructs; PMCA3: a mixed sample of 0.2–0.2 μg membrane protein from cells transfected with rPMCA3a, rPMCA3b constructs; PMCA4: a mixed
sample of 0.2–0.2 μg membrane protein from cells transfected with hPMCA4a, hPMCA4xb constructs. b: Relative protein expression of PMCA1,
PMCA4, SERCA2 and SERCA3 isoforms. Densitometric values were normalized to the respective β-actin levels and compared to the protein
expression of the non-tumorigenic MCF-10A cells in the case of PMCA1, PMCA4 and SERCA2, or to the protein expression of MCF-7 in the case of
SERCA3. Bars represent mean ± SEM from two independent experiments
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inhibitors significantly elevated histone H3 acetylation
without any effect on PMCA4b expression.
Impaired PMCA4b localization in triple negative cells
suggest loss of cellular function
A previous study demonstrated that PMCA4b can reach
the plasma membrane only in fully confluent HeLa cell
culture [51]. Similarly to these cells, PMCA4b was located
to the plasma membrane in all luminal type and HER2
positive cells displaying epithelial type cell morphology with
intact cell-cell contact sites (Figs. 3c and 4a-b). In order
to test the effect of the enhanced PMCA4b expression on
Ca2+ signaling, GCaMP2 expressing MCF-7 cells were
treated with VPA and challenged with the Ca2+ ionophore
Fig. 3 PMCA4b expression is selectively regulated during HDAC inhibitor treatments in breast cancer cell lines. Effects of valproate (VPA) and
suberoylanilide hydroxamic acid (SAHA) treatments on PMCA4b protein expression in different breast cancer cell lines. a: Cells were treated with
increasing concentrations of VPA or SAHA as indicated for 4 days, and PMCA4b protein expression from total cell lysates (15 μg protein per
sample) was analyzed by Western blotting with JA3 antibody. b: Relative PMCA4b expression after a 4 day VPA or SAHA treatment. Densitometric
values were normalized to the respective β-actin loading control levels and expressed as fold increase over the untreated controls. Bars represent
mean ± SEM from two to four independent experiments. c: Subcellular localization of the PMCA4b protein in VPA-treated cells. MCF-7, ZR-75-1,
BT-474 and BT-549 cells were treated with 2 mM VPA for 4 days. MCF-10A, AU-565, SK-BR-3, MDA-MB-468, MDA-MB-231 and Hs578T cells were
treated with 4 mM VPA for 4 days. After the treatments, every cell line was immunostained with an anti-PMCA4b antibody (JA3). Images were
taken by confocal microscopy. Scale bar: 30 μm
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Fig. 4 (See legend on next page.)
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A23187. Using this protocol we found that the enhanced
plasma membrane PMCA4b expression was accompanied
with an enhanced Ca2+ extrusion capacity of the cells, de-
creasing the amplitude and duration of the Ca2+ signal
(Fig. 4d-e). The basal type MDA-MB-231 cells represent a
more aggressive type of breast tumors that display an elon-
gated cell shape and a scattered pattern even at high dens-
ity. The lack of well-defined cell-cell contact sites can be
the reason why a large amount of PMCA4b seems to be lo-
cated in intracellular compartments in these cells (Figs. 3c
and 4a-b). Previously we showed that in HeLa cells the level
of confluency was important in the regulation of plasma
membrane localization of PMCA4b. In non-confluent
HeLa cell cultures a substantial portion of PMCA4b was
also located intracellularly [51]. In MDA-MB-231 cells VPA
treatment did not change the expression of the pump sig-
nificantly (Fig. 4c) in good correlation with the much less
pronounced effect of the treatment on the A23187 induced
Ca2+ transient (Fig. 4d-e). These experiments suggest that
in the basal type cells a considerable amount of PMCA4b is
located in intracellular compartments where it probably
cannot perform its plasma membrane-associated function
[51].
17β-estradiol enhances PMCA4b protein expression in
MCF-7 cells
Previous observations have shown that PMCA isoform
switch is a characteristic feature of the normal mammary
epithelial cell physiology during pregnancy and lactation,
suggesting that PMCAs are under hormonal control in the
breast [20, 52, 53]. To gain insight into the regulation of
PMCA expression in hormone receptor positive breast can-
cer cells, we examined if estrogen receptor alpha (ER-α) reg-
ulated PMCA expression in MCF-7 cells (Fig. 5a-b).
Because normal complete growth medium contains estro-
gen, and phenol-red that also displays estrogenic activity
[54], cells were cultured in a phenol-red free medium sup-
plemented with charcoal-stripped estrogen-free FBS before
and during 17β-estradiol (E2) treatments. We found a much
lower PMCA4b protein expression when cells were
cultured in this nominally hormone-free medium than in
the normal complete DMEM used in our previous experi-
ments. PMCA4b expression highly increased when
hormone-free medium was supplemented with E2. Further-
more, the pure ER-α antagonist fulvestrant (ICI 182,780)
completely reversed the E2-induced PMCA4b upregulation,
indicating that the effect of E2 was specific. It is important
to note that the expression of PMCA1 and SERCA3 slightly
decreased upon E2 treatment suggesting a mild compensa-
tory mechanism for the PMCA4b upregulation.
We then examined if the E2-induced changes in the
Ca2+ pump levels affected the Ca2+ signal in MCF-7 cells.
We performed Ca2+ signal measurements using a previ-
ously generated MCF-7 cell line that expresses the genet-
ically encoded Ca2+ indicator GCaMP2 [29]. We
preincubated GCaMP2-MCF-7 cells in E2-free medium
and then treated the cells with E2 or DMSO vehicle. Ca2+
signals were initiated by the addition of the Ca2+ ionophore
A23187, and changes in the fluorescence of the GCaMP2
sensor were monitored by confocal imaging (Fig. 5c and
Additional file 4: Figure S3). We found that in E2-treated
cells the Ca2+ peak was significantly smaller (Fig. 5d), and
the intracellular Ca2+ concentration returned to the
baseline level significantly faster than in the untreated cells
(Fig. 5e). These results suggest an enhanced Ca2+ extrusion
capacity of cells as a result of a net increase in PMCA ex-
pression in response to the E2-induced ER-α activity.
HDAC inhibitor treatment potentiates the ER-α-induced
PMCA4b expression in MCF-7 cells
Next, we combined E2 treatment with VPA or SAHA in
MCF-7 cells cultured in E2-free medium, and found that
combination of the two drugs further enhanced PMCA4b ex-
pression (Fig. 6). It is worth mentioning, however, that the
HDAC inhibitors alone - in the absence of E2 - also increased
PMCA4b abundance. The ER-α antagonist fulvestrant fully
reversed the E2-specific fraction of the PMCA4b upregula-
tion, whereas it did not alter the estrogen-independent effects
of HDAC inhibitors, indicating that additional regulatory
mechanisms are also involved.
(See figure on previous page.)
Fig. 4 PMCA4b localization and function is impaired in the triple negative MDA-MB-231 cell line. a: Cell culture morphology analysis of the MCF-7
and MDA-MB-231 cell lines. Pictures were taken with a phase contrast microscope. Gray cell masks were made using the ImageJ software v1.51j8
to emphasize the morphology of the cell cultures and cell-cell contacts. Scale bar: 30 μm. b: Subcellular localization of the PMCA4b protein in
VPA-treated MCF-7 and MDA-MB-231 cells. MCF-7 cells were treated with 2 mM VPA, MDA-MB-231 cell were treated with 4 mM VPA for 4 days
and immunostained with an anti-PMCA4b antibody (JA3). Images were taken by confocal microscopy. White arrows indicate PMCA4b protein in
intracellular compartments. Scale bar: 30 μm. c: Relative PMCA4b expression in MCF-7 and MDA-MB-231 cells after a 4 day VPA treatment.
Densitometric values of Western blots were normalized to the respective β-actin loading control levels and expressed as fold increase over
the untreated controls. Bars represent mean ± SEM from two to four independent experiments. d: Ca2+ signal measurements in VPA-treated
GCaMP2-MCF-7 and GCaMP2-MDA-MB-231 cells. Cells were treated with 4 mM VPA for 4 days. Before the measurement, culture medium was
replaced by HBSS supplemented with 2 mM Ca2+. Ca2+ influx was triggered by 2 μM Ca2+ ionophore A23187, and fluorescent signal of the
GCaMP2 Ca2+ sensor was followed by confocal imaging. F/F0 values represent individual cells (n = 14–32) from a representative experiment.
e: Area under curve of the A23187-induced Ca2+ transients. Bar graphs are means ± SEM of the individual cells (n = 14–32). Significance between
control and VPA-treated cells is denoted by *** (P < 0.001); two-tailed unpaired t-test
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Fig. 5 (See legend on next page.)
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Regulation of PMCA4 by ER-α is specific to the MCF-7 cell
line
We also examined the effect of E2 on PMCA4 expression
in other ER-α positive cell lines (T-47D, ZR-75-1, BT-474)
and in the ER-α negative MDA-MB-231 (Fig. 6 and Add-
itional file 5: Figure S4). E2 treatment did not influence
PMCA4 expression in any of these cells suggesting that the
regulation of PMCA4 level by ER-α was specific to MCF-7
cells. We showed, however, that ER-α was present in all of
the ER-α positive cells at a comparable level, and its expres-
sion decreased substantially after fulvestrant and HDAC in-
hibitor treatments, as expected [49]. Thus, all ER-α positive
cell lines reacted to fulvestrant, but PMCA4 expression
changed only in MCF-7 cells during the manipulation of
ER-α activity. This is an important finding since MCF-7
cells are often used as a model system for studying ER-α
positive breast tumor types.
To further study the role of ER-α in the regulation of
PMCA4 expression, we analyzed data from chromatin im-
munoprecipitation sequencing (ChIP-seq) experiments of
ER-α binding to the ATP2B4 gene locus in ER-α positive
breast cancer cells. We used the Cistrome Data Browser
[40, 41] to identify ER-α binding sites, and compared data
from different ChIP-seq libraries. Analysis of four inde-
pendent ChIP-seq data samples on MCF-7 cells identified
an active ER-α binding site in the intron 1 of the ATP2B4
gene (marked with red rectangle in Fig. 7). Within this re-
gion histone modification marks (H3K4Me1, H3K4Me3
methylation and H3K27Ac acetylation) were also observed
indicating the presence of regulatory binding sites. Next, we
compared ChIP-seq data of MCF-7, ZR-75-1 and T-47D
cells from experiments containing either MCF-7 and
ZR-75-1 or MCF-7 and T-47D data pairs and found that
ER-α bound to the ATP2B4 gene locus in MCF-7 cells, but
not in the other two ER-α positive cell lines ZR-75-1 and
T-47D (Fig. 7). These observations are in good correlation
with our experimental results demonstrating that among
the examined ER-α positive cell lines ER-α regulates
PMCA4 expression only in MCF-7 cells.
Discussion
Altered expression of the members of the Ca2+ signaling
toolkit frequently occurs during cancer progression.
However, the literature does not contain much published
research on Ca2+ pumps in tumors. In breast cancer
cells upregulated ATP2B1, ATP2B2 mRNA and down-
regulated ATP2B4 mRNA expressions were described
previously [24, 25]. Using bioinformatic tools we found
that the expression of the ATP2B4 gene is significantly
lower in invasive breast cancer tissue samples than in
normal breast tissue, while that of the ATP2B1 and
ATP2B2 genes did not show considerable differences.
However, in vitro examination of Ca2+ pump protein levels
in different breast cancer cell lines showed various expres-
sion levels of PMCA4b and other PMCA isoforms. The
function of isoform 2 in the normal physiology of breast
epithelium during lactation is well documented [52, 55–57].
More recent studies examined the role of PMCA2 in breast
cancer [26–28]. Comparing different breast cancer subtypes
we found that ATP2B2 mRNA expression was elevated in
basal type cancers, and correlated positively with survival
[28]. Controversially, elevated ATP2B2 expression was
found to be associated with poor clinical outcome in breast
cancer in another study [27]. PMCA2 also regulates HER2
signaling in HER2 positive breast cancer cells [26]. HER2
was found to interact with PMCA2 in specific membrane
domains where the low local Ca2+ concentration supports
sustained HER2 signaling and tumor growth [26]. In our in
vitro experiments PMCA2 protein expression was low in
all examined breast cancer cell lines, with PMCA1 and
PMCA4b being the main isoforms, although both were
expressed at variable levels. We found considerable
SERCA3 protein (encoded by the ATP2A3 gene) expres-
sion in all the examined luminal and HER2 overexpressing
cell lines, while it was not detectable in the triple negative,
basal subtype cells including MCF-10A. This observation is
in accordance with former studies that showed loss of
SERCA3 expression during tumorigenesis, and decreased
SERCA3 expression in triple negative breast cancers [15].
(See figure on previous page.)
Fig. 5 17β-estradiol enhances PMCA4b protein expression and activity in MCF-7 cells. 17β-estradiol (E2)-dependence of PMCA4b protein
expression and activity. a: MCF-7 cells were cultured in DMEM or in E2-free DMEM and treated with 1 nM E2 ± 100 nM fulvestrant (fulv.) for
4 days as indicated. Equal amount (30 μg) of total cell lysates were analyzed by Western blotting with isoform specific antibodies: anti-PMCA1
(NR1), anti-PMCA4b (JA3), anti-SERCA2 (IID8) and anti-SERCA3 (PL/IM 430). β-actin served as a loading control. b: Relative protein expression of
PMCA1, PMCA4b, SERCA2 and SERCA3 isoforms. Densitometric values were normalized to the respective β-actin levels and compared to the
protein expression of untreated cells cultured in DMEM. Bars represent mean ± SEM from three independent experiments. Significance is denoted
by * (P < 0.05) or ** (P < 0.01); two-tailed paired t-test. c: Ca2+ signal measurement in E2-treated GCaMP2-MCF-7 cells. Cells were cultured in E2-
free DMEM and treated with 1 nM E2 for 4 days. Before the measurement, culture medium was replaced by HBSS supplemented with 2 mM
Ca2+. Ca2+ influx was triggered by 2 μM Ca2+ ionophore A23187, and fluorescent signal of the GCaMP2 Ca2+ sensor was followed by confocal
imaging. Data represent means of normalized values (F/F0) ± 95% CI of 41 control and 59 E2-treated cells collected from three independent
experiments. d: Area under curve of the A23187-induced Ca2+ transients. Bar graphs are means ± SEM of the individual cells taken from three
independent experiments. Significance between control and E2-treated cells is denoted by *** (P < 0.001); two-tailed unpaired t-test. e: Half time
of decay of the A23187-induced Ca2+ transients. Bar graphs are means ± SEM of the individual cells taken from three independent experiments.
Significance between control and E2-treated cells is denoted by *** (P < 0.001); two-tailed unpaired t-test
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HDAC inhibitors such as VPA or SAHA are currently be-
ing developed for various types of malignancies, including
breast cancer [6, 58], and are already in clinical use for per-
ipheral T cell lymphomas [59, 60]. In this work VPA and
SAHA, two structurally different HDAC inhibitors in-
creased PMCA4b expression in breast cancer cells, and en-
hanced PMCA4b expression induced by E2 in MCF-7 cells.
Unlike that of E2, the effect of VPA and SAHA on
PMCA4b expression was not inhibited by fulvestrant.
These observations taken together indicate that PMCA4b
expression in MCF-7 cells is controlled by ER-α-, as well as
by HDAC-dependent chromatin remodeling. MCF-7 cells
constitute a unique in vitro model for the study of the
E2-dependent control of PMCA4b expression and of the
cross-talk between sex hormone and Ca2+ signaling
pathways.
The effect of the HDAC inhibitors was much less pro-
nounced in the triple negative cells, where the initial
PMCA4b expression was higher. We found that in the
triple negative MDA-MB-231 cells a considerable amount
of PMCA4b protein was located in intracellular compart-
ments, suggesting that PMCA4b cannot perform its plasma
membrane-associated function, similarly to that seen in
non-confluent HeLa cells [51]. It is important to note that
Fig. 6 17β-estradiol enhances PMCA4 expression specifically in MCF-7 and further enhances the HDAC inhibitor induced upregulation. Effects of
17β-estradiol (E2) ± HDAC inhibitor treatments on PMCA4 protein expression in ER-α positive breast cancer cell lines. a: MCF-7, ZR-75-1 and T-47D
cells were cultured in E2-free culture medium and treated with 1 nM E2 ± 100 nM fulvestrant (fulv.) ± 4 mM VPA or 3 μM SAHA for 4 days as
indicated. Equal amount (30 μg) of total cell lysates were analyzed by Western blotting with anti-PMCA4 (JA9), anti-ER-α and anti-ER-β antibodies.
β-actin served as a loading control. b: Relative PMCA4 protein expression in the examined cell lines. Densitometric values were normalized to the
respective β-actin levels and expressed as fold increase over the untreated controls. Bars represent mean ± SEM from three independent
experiments. Significance is denoted by * (P < 0.05) or ** (P < 0.01); two-tailed paired t-test
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mislocalization of other proteins, including those with
tumor suppressor function has been reported in association
with cancer development and metastasis [61]. It has been
shown that ER-α positive breast tumors express HDAC
proteins at higher amounts [49, 50], and that the antiprolif-
erative effect of HDAC inhibitors is also more potent in the
ER-α positive breast cancer cell lines [62]. Therefore, it is
not surprising that in our experiments HDAC inhibitors
showed higher effect on PMCA4b expression in the lu-
minal type cell lines. However, histone acetylation levels
and PMCA4b upregulation did not correlate tightly in the
HER2 overexpressing or basal cell lines. ATP2A3 mRNA
was found to be overexpressed after HDAC inhibitor treat-
ment both in the MCF-7 and MDA-MB-231 cell lines [63]
but we could not find any significant changes in SERCA3
protein expression in response to VPA or SAHA. Several
studies aim to elucidate the mechanism of HDAC inhib-
ition to develop more potent strategies for cancer treat-
ment. Some of these studies showed that HDAC inhibitors
induced expression of ER-α in triple negative breast cancer
cell lines or reversed hormone resistance of the ER-α posi-
tive cells [49, 64, 65]. These ER-α negative or tamoxifen/
aromatase inhibitor-resistant breast tumors could be sensi-
tized to anti-estrogen therapies by HDAC inhibitors that in-
duce the expression of the epigenetically repressed ER-α
receptor. Clinical trials have also been performed with
HDAC inhibitors alone or in combination with tamoxifen
[64, 66]. Although, some results were promising, controver-
sial data were also reported in other studies, in which
HDAC inhibitors did not induce ER-α expression in the
triple negative breast cancer cells [6, 67]. In our experi-
ments ER-α protein expression in MDA-MB-231 cells was
also not affected by VPA or SAHA.
As we already mentioned above, here we describe for the
first time that activation of the ER-α pathway increases
PMCA4b protein expression in MCF-7 cells. However, the
expression of the protein did not change in the other exam-
ined ER-α positive breast cancer cell lines ZR-75-1, T-47D,
BT-474 or in the ER-α negative MDA-MB-231 cells. Our
results are in line with those studies that report complex
regulation of the ER-α-induced transcription of target genes
[34, 64, 68]. The in-depth analysis of a gene chip assay re-
vealed upregulation of the ATP2B4 gene in response to E2
stimulation of MCF-7 cells [68]. Interestingly, ATP2B4 was
also upregulated by E2 in MDA-MB-231 cells stably ex-
pressing exogenous ER-α [68]. Stender et al. discussed that
the ability of ER-α to regulate gene expression in different
cell lines in a different way depended on many factors, such
as varying transcription factor expression and activity, dif-
ferent chromatin structure or epigenetic modifications [68].
Hilborn et al. examined the effect of E2 on the expression
of hydroxysteroid 17β-dehydrogenase (HSD17B) 1 and 2
[69]. The protein products of HSD17B1 and HSD17B2 play
an important role in controlling E2 activity. In their experi-
ments HSD17B2 expression was upregulated after a 7-days
E2 treatment in MCF-7 but not in T-47D and ZR-75-1 cells
[69]. This result further supports the idea that different
ER-α positive breast cancer cell lines use different regula-
tory pathways in response to ER-α activation, and are in ac-
cordance with our results indicating that among the ER-α
positive cell lines only MCF-7 is E2-responsive in terms of
elevation of PMCA4b expression.
The G protein-coupled estrogen receptor 1 (GPER/
GRP30) plays a role in non-genomic ER-α signaling [64].
Besides mediating a wide range of cellular processes, such
as activation of the cAMP, ERK1/2 and PI3K pathways or
Fig. 7 ATP2B4 gene has an ER-α bindig site in the intron 1 in MCF-7 cells. The human ATP2B4 locus (chromosome 1, 1q32.1) in the UCSC Genome
Browser (Human Dec. 2013 (GRCh38/hg38) Assembly) [47, 48]. The RefSeq ATP2B4 transcript contains the untranslated exon 1 and 22 protein
coding exons. Arrows mark transcriptionally important sites according to histone methylation and acetylation patterns. Binding site of ER-α
(obtained from ChIP-seq data of Cistrome database [40, 41]) is marked with red rectangle. ChIP-Seq data were sourced from GSM2467223 [Dzida
et al., unpublished], GSM2040043 [46], GSM986063 and GSM986089 from series GSE40129 [45], GSM798424 and GSM798428 from series
GSE32222 [44]
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intracellular Ca2+ mobilization [70], GPER/GRP30 can
affect metastasis progression, as it was reported to regulate
the cell-matrix adhesion of MCF-7 cells through the ERK1/
2-calpain pathway [71]. Previously, PMCA4 was found to
form a protein complex with the GPER/GRP30, in which
GPER/GPR30 inhibits PMCA4 activity and PMCA4 also af-
fects GPER/GRP30 function [72]. GPER/GPR30 was de-
scribed as a E2-binding receptor, but it can be activated
both by E2 and the pure ER-α antagonist fulvestrant [70].
In our experimental system, fulvestrant completely inhib-
ited the E2-induced PMCA4 upregulation, suggesting that
GPER/GPR30 is not involved in this process. Further stud-
ies are needed to clarify the exact mechanisms of E2 on the
regulation of Ca2+ pump expression.
E2-dependent signaling is central for the physiological
regulation of normal breast epithelial cell function,
growth, differentiation and survival, and estrogen directs
the growth also of ER-α positive breast cancer cells [73].
Antiestrogen therapy by agents such as fulvestrant is
therefore a mainstay of ER-α positive breast cancer ther-
apy [74]. Data presented in this work show that ER signal-
ing, and its pharmacological modulation modify the Ca2+
homeostasis of cells via the regulation of PMCA4b expres-
sion. It has been shown earlier that, due to its slow activa-
tion/inactivation kinetics, the presence or the absence of
PMCA4b determines the spatiotemporal characteristics of
SOCE-type Ca2+ transients and oscillations [19], which in
turn affect cell survival, motility and proliferation. In
addition, PMCA4b expression has been shown earlier in
normal ductal mammary epithelial cells in situ [29]. The
demonstration of the E2 dependency of PMCA4b expres-
sion is therefore an interesting new aspect of mammary
epithelial cell differentiation present in ER-α positive breast
cancer cells, that constitutes a previously unknown mech-
anism of cross-talk between E2- and Ca2+-dependent sig-
naling. This may be exploited in the future, for example for
devising new combination anticancer therapies whereby
E2- and Ca2+-dependent signaling mechanisms are simul-
taneously targeted in breast cancer cells.
It is also well known that the expression of various PMCA
isoforms is tightly regulated in breast tissue, especially during
pregnancy and lactation [55–57], further highlighting the
physiological importance of our findings. The main PMCA
isoform is PMCA4b in the developing rat mammary tissue,
and its expression is increased during pregnancy. However,
PMCA4b protein shows a major rapid downregulation after
parturition when PMCA2b is significantly upregulated, and
plays an essential role in transporting Ca2+ into the milk dur-
ing lactation [52]. The changes in PMCA4b abundance coin-
cided with gradually increasing serum E2 levels during
pregnancy that drastically drop prior to parturition [75].
While further evidence is needed to prove a direct interaction
between the ER and PMCA4, these results suggest that the
effect of E2 on PMCA4 expression is physiologically relevant.
Moreover, the altered PMCA4 expression and the reshaped
Ca2+ signal pattern in breast tumor cells suggest that the pro-
tein might have an important role in neoplasia.
Conclusions
In this study we found that the expression of Ca2+ pumps is
differentially regulated by epigenetic drugs and estradiol in
breast cancer cell lines having different genetic backgrounds.
HDAC inhibitor treatments induced pronounced upregula-
tion of the PMCA4b protein in ER-α positive luminal type
cells. Importantly, we show for the first time, that the ER-α
pathway upregulates PMCA4b expression specifically in the
MCF-7 cell line. Identification of an active ER-α binding site
in the ATP2B4 gene in MCF-7 cells further supports our ex-
perimental observation. Our work also shows that changes in
Ca2+ pump expression levels shape calcium extrusion and
thus the intracellular Ca2+ signals that can further affect sev-
eral downstream signaling pathways.
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Additional file 1: Table S1. Breast cancer cell lines and their
characteristics used in this study [2, 3, 32–34]. (PDF 185 kb)
Additional file 2: Figure S1. Effects of VPA and SAHA treatments on
Ca2+ pump expressions in different breast cancer cell lines. A: Cells were
treated with increasing concentration of VPA or SAHA as indicated for
4 days, and protein expressions from total cell lysates (15 μg protein per
sample) were analyzed by Western blotting with isoform specific
antibodies: anti-PMCA1 (NR1), anti-SERCA2 (IID8) and anti-SERCA3 (PL/IM
430). B: Relative PMCA1, SERCA2 and SERCA3 protein expressions after a
4 day VPA or SAHA treatment. Densitometric values were normalized to
the respective β-actin loading control levels and expressed as fold in-
crease over the untreated controls. Bars represent mean ± SEM from two
to four independent experiments. (TIF 5113 kb)
Additional file 3: Figure S2. Effects of VPA and SAHA treatments on
PMCA4b protein expression and histone H3 acetylation level in different
breast cancer cell lines. A: Cells were treated with 4 mM VPA or 3 μM
SAHA for 4 days, and protein expressions from total cell lysates (30 μg
protein per sample) were analyzed by Western blotting with JA9 and
anti-acetyl-histone H3 antibodies. B: Relative protein expressions from a
representative experiment. Densitometric values were normalized to the
respective β-actin loading control levels, and expressed as fold increase
over the untreated controls in the case of each cell line. (TIF 990 kb)
Additional file 4: Figure S3. Ca2+ signal measurement in E2-treated
GCaMP2-MCF-7 cells. Cells were cultured in E2-free DMEM and treated
with 1 nM E2 for 4 days. Before the measurement, culture medium was
replaced by HBSS supplemented with 2 mM Ca2+. Ca2+ influx was trig-
gered by 2 μM Ca2+ ionophore A23187, and fluorescent signal of the
GCaMP2 Ca2+ sensor was followed by confocal imaging. F/F0 values rep-
resent individual cells (41 control and 59 E2-treated cells) collected from
three independent experiments. (TIF 602 kb)
Additional file 5: Figure S4. Effects of 17β-estradiol (E2) ± HDAC inhibitor
treatments on PMCA4 protein expression in the ER-α positive BT-474 and in
the ER-α negative MDA-MB-231 breast cancer cell lines. A: BT-474 and MDA-
MB-231 cells were cultured in E2-free culture medium and treated with 1 nM
E2 ± 100 nM fulvestrant (fulv.) ± 4 mM VPA or 3 μM SAHA for 4 days as indi-
cated. Equal amounts (30 μg) of total cell lysates were analyzed by Western
blotting using the anti-PMCA4 (JA9), anti-ER-α and anti-ER-β antibodies. β-actin
served as a loading control. B: Relative PMCA4 protein expression in the exam-
ined cell lines. Densitometric values were normalized to the respective β-actin
levels and expressed as fold increase over untreated controls. Bars represent
mean ± SEM from three independent experiments. (TIF 915 kb)
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